Navigation Links
Covance Reports Second Quarter Revenue of $518 Million, GAAP EPS of $0.61, and Pro Forma EPS of $0.66
Date:7/27/2011

PRINCETON, N.J., July 27, 2011 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today reported GAAP earnings for its second quarter ended June 30, 2011 of $0.61 per diluted share.  Included in second quarter results is $0.05 per diluted share in costs from the previously-announced restructuring actions. Excluding these costs, earnings per diluted share were $0.66 in the quarter.  

"On a consolidated basis, second quarter net revenues grew 9.1% year-on-year and pro forma operating margin (when excluding $4.6 million of restructuring costs), expanded 80 basis points sequentially to 10.3%," said Joe Herring, Chairman and Chief Executive Officer.  "In Early Development, revenues grew 11.4% year-on-year to $231.8 million. Revenues were up sequentially in toxicology, analytical chemistry, clinical pharmacology, and discovery support, driving a $7.8 million increase in revenues and a 240 basis point increase in pro forma operating margin from last quarter to 14.2%.  In Late-Stage Development, revenues grew 7.3% year-on-year and 3.0% sequentially driven by the continued strong performance in clinical development coupled with the weakening of the US dollar, which more than offset the impact of continued project delays and cancellations in central laboratories. Pro forma operating margin in the segment was 20.0%.  

"On the commercial front, adjusted net orders in the second quarter were $614 million, representing an adjusted book-to-bill of 1.18 to 1 led by continued strong orders across all phases of clinical development.  Looking forward, we are encouraged by the increasing demand for our early development services, including toxicology, as well as the continued robust pipeline of clinical development proposals. In order to fully capitalize on the market opportunities we are seeing, several dozen incremental sales and marketing professionals were hi
'/>"/>

SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Covance to Present at Bairds 2011 Growth Stock Conference
2. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2011 Financial Results Conference Call
3. Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference
4. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
5. Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56
6. Covance Reports Third Quarter Financial Results and Takes Actions to Strengthen Future Performance
7. Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R&D Alliance
8. Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
9. Covance Board Authorizes $250 Million Stock Buyback
10. Covance to Present at Morgan Stanley Global Healthcare Conference
11. Covance to Present at William Blair & Companys 30th Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral ... results from its Phase IIa clinical trial of ... treat type 1 diabetes. The trial was conducted in ... a U.S. Food and Drug Administration (FDA) Investigational ...
(Date:10/22/2014)... Oct. 21, 2014 Influenza will affect as many ... the United States as high as ... to spread is from person to person in respiratory droplets ... serve way of death, but kills much fewer people each ... done by human fluids including sweat, saliva, blood and other ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 WHEN: ... EDTLOCATION: Online, complimentary registration available at: ... Leader Archana Vidyasekar and Visionary Innovation Research ... WiFi-like wireless electricity, self-assembling materials, nanobots and ... technologies which will transform our lives in ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4
(Date:10/25/2014)... Homeowners that are wondering how they can tell ... more. Clean Crawls gives 5 signs of poor ... it comes to insulation in their recently released article. ... Clean Crawls, can cause problems throughout your entire home. ... deteriorated, become damp, or been infested with pests should ...
(Date:10/25/2014)... 2014 Limbkeepers® announced today that they ... with Ed Begley Jr, airing 1st QTR 2015 via ... this episode, Innovations will focus on Limbkeepers® non compression ... thinning skin on arms, hands, and legs from abrasion, ... versatile products, which help reduce injuries, allow for continued ...
(Date:10/25/2014)... News) -- Not getting the right amount of sleep ... study suggests. Those who sleep less or more ... may be more prone to developing the chronic condition, ... study authors concluded that duration and quality of sleep ... inflammatory bowel diseases. "Both short and long durations ...
(Date:10/25/2014)... Oct. 23, 2014 (HealthDay News) -- Current osteoporosis ... younger postmenopausal women at risk for osteoporosis-related fractures, ... to prevent fractures, we need tools that help ... injuries so that we can target these at-risk ... Crandall, professor of medicine in the division of ...
(Date:10/22/2014)... October 22, 2014 At a time ... among parents and athletes at all levels, the ... change the current discussion where two powerful messages are ... therapies that result in full recoveries every day. , ... based in fact and research, UPMC and the Concussion ...
Breaking Medicine News(10 mins):Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4
... is used widely for colonoscopic exploration and colonic ... is the osmotic laxative most commonly used for ... induce severe hyperphosphatemia and hypocalcemia due to excessive ... of deaths and irreversible dialysis-requiring renal insufficiency. However, ...
... mellitus is one of the most common chronic disease ... is over 10% in Taiwan. Gastroparesis is reported in ... (SMA) syndrome is an uncommon disease resulting compression of ... mesenteric artery. However, SMA syndrome can cause the same ...
... ... begun the new year by expanding their existing Green Bay, WI presence with the ... ... growing technology company representing both businesses and residents has joined forces with Buildmyownsite, Inc., ...
... emergency department, federal report shows , THURSDAY, Jan. 14 ... million motor vehicle crash victims who had injuries ranging ... a new government study finds. , About 85 percent ... 321,000 were admitted or transferred to another acute care ...
... ... mental tasks is highly predictive of crash risk and a small amount of ... to research presented this week at the 2010 annual meeting of the ... the age wave of 70 million baby boomers begins to join the ranks ...
... , ... Dentist Honored in 2010 Edition of Who’s Who as dentist of the year. ... New York, NY (Vocus) January ... convenience, has been honored by the Presidential Who’s Who organization as dentist of the year. ...
Cached Medicine News:Health News:Infinity Technology, Inc. Acquires Build My Own Site, Inc. 2Health News:Brain Fitness Predicts Crash Risk 2Health News:Brain Fitness Predicts Crash Risk 3Health News:Brain Fitness Predicts Crash Risk 4Health News:Dr. Jan Linhart to Appear in Presidential Who's Who Among Business and Professional Achievers 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: